IRIS publication 235380067
Medical-Treatment of Inflammatory Bowel-Disease
RIS format for Endnote and similar
TY - JOUR - Shanahan, F.,Targan, S. - 1992 - Medical-Treatment of Inflammatory Bowel-Disease - Validated - () - 43 - 125 - 133125 - Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease.Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease. - 0066-42190066-4219 - ://WOS:A1992HL70900012://WOS:A1992HL70900012 DA - 1992/NaN ER -
BIBTeX format for JabRef and similar
@article{V235380067, = {Shanahan, F. and Targan, S. }, = {1992}, = {Medical-Treatment of Inflammatory Bowel-Disease}, = {Validated}, = {()}, = {43}, pages = {125--133125}, = {{Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease.Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease.}}, issn = {0066-42190066-4219}, = {://WOS:A1992HL70900012://WOS:A1992HL70900012}, source = {IRIS} }
Data as stored in IRIS
AUTHORS | Shanahan, F.,Targan, S. | ||
YEAR | 1992 | ||
MONTH | |||
JOURNAL_CODE | |||
TITLE | Medical-Treatment of Inflammatory Bowel-Disease | ||
STATUS | Validated | ||
TIMES_CITED | () | ||
SEARCH_KEYWORD | |||
VOLUME | 43 | ||
ISSUE | |||
START_PAGE | 125 | ||
END_PAGE | 133125 | ||
ABSTRACT | Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease.Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate (5-ASA), topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators. These novel therapeutic approaches have emerged from pharmaceutical improvements on traditional drugs and also from an improved understanding of the mucosal immune system and the pathogenesis of inflammatory bowel disease. | ||
PUBLISHER_LOCATION | |||
ISBN_ISSN | 0066-42190066-4219 | ||
EDITION | |||
URL | ://WOS:A1992HL70900012://WOS:A1992HL70900012 | ||
DOI_LINK | |||
FUNDING_BODY | |||
GRANT_DETAILS |